UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage  Irvine, Calif., May 13, 2019 — In hopeful news…
Browsing: Acute Lymphoblastic Leukemia
Philadelphia, PA (May 3, 2019) – Oncoceutics, Inc. announced the publication of two scientific research articles demonstrating that members of…
Composition of Matter Patent and Translational Research Grant issued for ONC213Philadelphia, PA (April 30, 2019) – Oncoceutics, Inc. announced that…
Philadelphia, PA (April 24, 2019) – Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant…
NEW DATA SHOW BLUEPRINT® IDENTIFIES ESTROGEN RECEPTOR POSITIVE BREAST CANCER PATIENTS WITH POOR RESPONSE TO ANTI-ESTROGEN THERAPY WHO MAY BENEFIT FROM…
Philadelphia, PA (April 9, 2019) – Oncoceutics announced today the publication of an article entitled “First clinical experience with DRD2/3…
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million…
SOUTH SAN FRANCISCO, Calif., April 2, 2019 /PRNewswire/ –Â ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery…
April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics   Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in…
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of…
Laurence Albiges, Gustave Roussy Villejuif, France discusses HIF-2aa new target in metastatic RCCat the Kidney Cancer Association International Symposium 2019…
Toni K. Choueiri, MD of Dana-Farber Cancer Institute, Boston, MA discusses A First-in-Human Phase 1/2 Trial of the Oral HIF-2a…
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active…
John B. Haanen MD PhD Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital asks the question…
Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe  Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced…
John B. Haanen MD PhD gives the Fitzpatrick Memorial Lecture entitled Do we need a new Carmena in the IO…
Following the news on March 19, 2019 that Merck KGaA and Pfizer have discontinued the ongoing Phase III JAVELIN Ovarian…
AUBURNDALE, Mass., March 21, 2019 /PRNewswire/ – Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a…
(Kanazawa, 21 March 2019) Researchers at Kanazawa University report in Nature Communications what causes some lung-cancer patients to have an…
March 11, 2019 07:37 PM Eastern Daylight Time  NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced the United States…
On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in…
March 18, 2019 BOULDER, Colo., March 18, 2019 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National…
Philadelphia, PA (February 22, 2019) – Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health…
Read press release online:Â https://ir.moleculin.com/press-releases/detail/117/moleculin-files-with-fda-for-expedited-approval-pathway-for HOUSTON, TX- March 13, 2019 -Â Moleculin Biotech, Inc., (NASDAQ: MBRX)(“Moleculin” or the “Company”), a clinical stage…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combination Pembrolizumab And Olaparib In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses How To Treat mRCC After Combination I-O In The…
Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd. Philadelphia, PA (February 15, 2019) – Oncoceutics, Inc. announced…
(WASHINGTON, March 12, 2019) — Yesterday, President Donald Trump released a fiscal year 2020 budget request that proposes a 12…
Wood LS, Hoffner B, Rubin K, Davies MJ, Tushla LA, Guild V, Guild SR. Background Immune checkpoint inhibitors (ICIs) have…
Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses CAR-T Therapy…
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, Discusses…
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Reliability Of The…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Outcomes Of The ECHELON-2 Study.…
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses…
Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
James McClosky, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Using Newly FDA…
Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Outcomes…
Nizar Bahlis, MD University of Calgary, Calgary, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on…
Nizar Bahlis, MD University of Calgary, Calgary, discusses Current Maintenance Regimens For MM. At The 60th ASH Annual Meeting on…